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Abstract
Background: Vitamin D is important for bone mass accrual during growth. Additionally, it is considered a
requirement for a multitude of processes associated with, for example, the development of immunity. Many
countries apply vitamin D supplementation strategies in infants, but the guidelines are not based on scientific
evidence and aim at prevention of rickets. It remains unclear whether the recommended doses are sufficient for
the wide array of other effects of vitamin D. The VIDI trial performed in Finland is the first large randomised
controlled study for evaluation of the effects of different vitamin D supplemental doses in infancy on:
1. bone strength
2. infections and immunity
3. allergy, atopy and asthma
4. cognitive development
5. genetic regulation of mineral homeostasis
Methods/Design: VIDI, a randomised controlled double-blinded single-centre intervention study is conducted in
infants from the age of 2 weeks to 24 months. Participants, recruited at Helsinki Maternity Hospital, are randomised
to receive daily either 10 μg (400 IU) or 30 μg (1 200 IU) of vitamin D3 supplementation. Both groups are assessed
at 6 months of age for calcium homeostasis, and at 12 and 24 months of age for parameters associated with bone
strength, growth, developmental milestones, infections, immunity, atopy-related diseases, and genetic factors
involved in these functions.
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Discussion: The study enables evaluation of short and long term effects of supplemental vitamin D on growth,
immune functions and skeletal and developmental parameters in infants, and the effects of genetic factors therein.
The results enable institution of evidence-based guidelines for vitamin D supplementation in infancy.
Trial registration: ClinicalTrials.gov, NCT01723852, registration date 6.11.2012.
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Background
The biologically inactive vitamin D3 (cholecalciferol) is
produced in the skin after solar UVB exposure. It is
bound to vitamin D binding protein (DBP) and trans-
ported to the liver for conversion to 25-hydroxy-vitamin
D (25-OHD), the most abundant circulating metabolite
of vitamin D. In the kidney, 25-OHD is further hydrox-
ylated to the active form calcitriol, 1,25-OH2D, that con-
tributes to calcium metabolism [1]. Paracrine conversion
of 25-OHD to calcitriol occurs in many tissues, such as
dendritic and endothelial cells, brain, placenta and para-
thyroids, underscoring the importance of vitamin D for
these organs [2]. Based on the number of cell types ex-
pressing vitamin D receptors (VDR), 38 potential target
tissues have been recognised [3]. In target cells, calcitriol
regulates the transcription of target genes, including sev-
eral genes involved in cell cycle regulation [4]. Locally
produced calcitriol in immune cells participates in host
defence reactions and acts as a potent immunomodula-
tor [2, 5]. In fact, vitamin D has been estimated to dir-
ectly and indirectly regulate the expression of 2–3% of
the human genome [4].
Both cutaneously synthesised and dietary vitamin D
contribute to the circulating 25-OHD concentration.
There is no consensus on the optimal 25-OHD concentra-
tion. In 2011, Institute of Medicine guideline stated that
25-OHD concentrations above 50 nmol/L are required for
normal body functions including linear growth and bone
mass accrual [6]. According to the Endocrine Society [7],
for optimizing long-term health benefits such as the pre-
vention of diabetes or fractures, concentrations above
75 nmol/L may be needed.
Vitamin D supplementation has been recommended in
Finland for all infants since the 1940’s, but in line with
the declining prevalence of rickets, the recommended
doses have gradually decreased. The present Finnish Nu-
tritional Council guidelines recommend 10 μg (400 IU)
of vitamin D3 supplementation daily for all infants from
the age of 2 weeks to 24 months, and 7.5 μg (300 IU) to
children aged 2 to 18 years. Despite these recommenda-
tions, 20% of children were shown to be vitamin D defi-
cient (<50 nmol/L) at 14 months of age [8]. In addition,
we have previously shown that more than 70% of 195
apparently healthy school children in Helsinki, Finland,
were vitamin D deficient (<50 nmol/L) during the school
year [9, 10].
Role of vitamin D in health and disease
Growth and bone mineralisation
Serum calcium and phosphate concentrations are tightly
regulated by parathyroid hormone (PTH) and 1,25-
OH2D by negative feedback. Rickets is caused by insuffi-
cient vitamin D supply resulting in the lack of sufficient
calcium and phosphate for bone mineralization at the
growth plates [11]. The worldwide incidence of rickets is
increasing [11]. Vitamin D deficiency is associated with
low bone mineral density (BMD) and an unfavourable
bone development in children aged 6–16 years and in
newborns [12, 13]. However, data on the relationship be-
tween vitamin D and BMD in children are somewhat
contradictory. In healthy children aged 8–17 years with
S-25-OHD levels above 50 nmol/L, no effect of vitamin
D supplementation on BMD is seen [14], and the rela-
tionship between BMD and S-25-OHD is inconsistent in
infants and young children [15].
In infants, severe vitamin D deficiency (<25 nmol/L)
associates with poor linear growth and delayed motor
development possibly due to muscle weakness [16, 17].
In vitamin D deficient children, vitamin D supplementa-
tion improved growth velocity and prevented stunted
growth [18, 19]. The increase in S-25-OHD concentra-
tion increased circulating IGF-1 level [18].
Infections and immunity
Rickets commonly presents with comorbidities such as
continuous or recurrent respiratory infections [20, 21].
Vitamin D has profound effects on the immune system
by promoting immune responses and inducing innate
immune defences. Immune cells express vitamin D recep-
tor (VDR) and respond to vitamin D [22, 23]. On innate
immunity, vitamin D inhibits the expression of pattern-
recognition receptors, induces autophagy in macrophages
and induces endogenous antimicrobial peptides, such as
cathelicidin. On adaptive immunity, for example, vitamin
D acts by regulating the release of pro-inflammatory
cytokines from mononuclear cells and inhibits T-cell
proliferation through decreased Th1 cytokine secretion
[24–26]. Therefore, vitamin D does not only have a role in
Helve et al. BMC Pediatrics  (2017) 17:91 Page 2 of 8
modulating host defence to infections, but is likely to con-
trol factors in autoimmunity, also in allergic disease.
Vitamin D modifies response to both bacterial and
viral infections [24, 27]. In adults, vitamin D insuffi-
ciency increases the risk of severe infections [28], but
the results from intervention trials are conflicting [29].
Vitamin D deficiency may contribute to increased occur-
rence of lower respiratory tract infections in children [30].
In 167 Japanese children aged 6–16 years a supplemental
vitamin D3 of 1 200 IU for a period of 4 months resulted
in a significant reduction in influenza A infections [31]. In
addition, vitamin D deficiency is associated with upper
respiratory tract, gastrointestinal and ear infections in
children [32, 33]. Identification, treatment, and prevention
of vitamin D deficiency in early childhood may therefore
have widespread health effects throughout childhood.
Allergy, atopy and asthma
In Finland, the prevalence of asthma among children aged
7–16 years is 7% [34]. Based on epidemiological studies,
low maternal intake of vitamin D at pregnancy and low
cord blood 25-OHD concentration have been associated
with a higher risk for asthma, allergic rhinitis and atopic ec-
zema in the offspring, as assessed at 5 years of age [35–38].
However, findings have not been consistent [39] and recent
studies on prenatal vitamin D supplementation have not
demonstrated an effect on wheezing at 3 years of age [40,
41]. Vitamin D may, however, have a protective effect
against childhood wheezing and asthma, but the evidence
is inconclusive [42]. In adults, IgE concentrations are higher
for those adults with low or very high concentration of
serum 25-OHD (S-25-OHD) [43].
Cognitive development
The association between concentrations of S-25-OHD
and cognitive abilities has been widely studied among
middle-aged and older individuals [44–46]. Vitamin D
trials are rare and they have not been able to support
beneficial effects of vitamin D supplementation on cogni-
tive functions among adults [47, 48]. Little evidence exists
on the effects of vitamin D on the cognitive development
among children and adolescents. Low concentrations of
cord blood 25-OHD increased the risk for delayed mental
and psychomotor development in 363 16–18-months-old
children with severe vitamin D deficiency [49]. Surpris-
ingly, also the children with the highest S-25-OHD
concentrations had deficits in psychomotor development.
However, S-25-OHD concentrations were not associated
with cognitive performance in adolescents after control-
ling for ethnicity [50–52]. Although preliminary results
point to importance of early life exposure, the role of
vitamin D in cognitive development during childhood and
adolescence remains largely unstudied.
Genetic regulation of mineral homeostasis
S-25-OHD concentration has high heritability (28–80%),
which explains differences in responses to vitamin D
supplementation [53]. Genome-wide association studies
on vitamin D insufficiency identified a number of com-
mon genetic variants that influence 25-OHD concen-
trations and the risk of insufficiency [54]. These
included single nucleotide polymorphisms in the GC
gene encoding vitamin D binding protein, locus near
the 7-dehydrocholesterol reductase involved in vitamin D
synthesis in the skin, and CYP2R1 coding cytochrome
P450 responsible for 25-hydroxylation. We have studied
GC polymorphisms in relation to vitamin D metabolism
and bone strength in children [55] and observed differ-
ences in S-25-OHD and PTH concentrations between GC
genotypes and that variation exists in BMD and bone
strength index as well. The variation in S-25-OHD be-
tween GC genotypes suggests differences in vitamin D
utilisation. Polymorphisms of the vitamin D receptor gene
VDR associate with growth pattern in infancy [56, 57] and
with bone strength [58]. VDR polymorphisms together
with vitamin D supplementation affect bone mineral
accrual suggesting that vitamin D supplementation could
be used to change the developmental trajectory and in-
duce phenotype with lowered risk for chronic disease or
disorder [59, 60]. Other possible candidate genes include
CYP24A1 that encodes 24-hydroxylase initiating degrad-
ation of both 25-OHD and 1,25-OHD [54].
Overall aims and research questions
The aim of the study is to investigate long-term health
benefits of early vitamin D supplementation with a dose
ensuring effective concentration of 25-OHD.
The primary outcomes of the study are bone strength
and cumulative frequency of infections at 24 months of
age. We hypothesise that a higher vitamin D supplementa-
tion to infants between 2 weeks and 24 months of age will
increase bone strength and decrease the frequency of
infections.
Secondary outcomes of the study are occurrence of IgE
mediated allergic symptoms, growth, motor, cognitive and
social development, and associations of concentration and
effects of vitamin D with polymorphisms of genes associ-
ated with its synthesis, binding proteins and degradation.
Methods/Design
Study design and setting
This is a randomised on-going controlled double-blinded
intervention trial on children of 2 weeks to 24 months of
age (Fig. 1). Vitamin D supplementation was commenced
at 2 weeks of age and continued until 24 months of age.
This study is carried out at the Kätilöopisto Maternity
Hospital, Helsinki, Finland (60°20,40’N). The hospital is
one of three hospitals providing maternity services for
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the greater Helsinki area (a population of 1.5 million)
with 8 000 births annually (15 000 in the whole greater
Helsinki area).
Research team
The research team responsible for inception, implemen-
tation, and management of the protocol includes paedia-
tricians, paediatric specialists in the field of neonatology,
endocrinology, infectious diseases and immunology, psy-
chologists, and nutritionists. The research team and the
research nurses undertake recruitment, data collection,
follow-up visits, and data entry.
Procedure and participants
A total of 4 980 infants were assessed for eligibility and
1 572 did not meet the inclusion criteria. Written infor-
mation of the study was given to 3 408 families at the
Helsinki Maternity Hospital 1–2 days after delivery from
which 2 421 declined to participate. Altogether 987
healthy term newborns were recruited between January
2013 and June 2014.
The participating mothers were of Caucasian origin,
without regular medication and with a singleton preg-
nancy. The infants were born at term (37 + 0 to 42 +
0 weeks) with a birth weight appropriate for gestational
age (birth weight SD score between −2.0 to +2.0). Exclu-
sion criteria for the infants were nasal continuous posi-
tive airway pressure treatment for more than 1 day,
intravenous glucose infusion, intravenous postnatal anti-
biotic treatment, seizures, duration of phototherapy for
more than 3 days, and need for nasogastric tube for
more than 1 day.
Girls (492) and boys (495) were randomised at recruit-
ment in blocks of 50 to receive either 10 or 30 μg of
vitamin D3 (400 IU or 1 200 IU, respectively) daily dur-
ing the study period. Randomisation was performed by
an external pharmacist and was blinded from the study
group.
Vitamin D is administered once daily with 5 drops for
both concentrations. The families received a study diary
to record treatment compliance prospectively and empty
vitamin D bottles are collected at follow-up visits.
Each family keep record of the child’s infections on a
study diary throughout the study period. Data on allergic
symptoms, growth, child’s motor and neurocognitive
functioning, mental and behavioural health, social skills,
sleep and diet are also collected. Furthermore, mothers
report their own well-being at child’s birth (questionnaires
given at recruitment) and at 12- and 24-month follow-up.
Follow-up visits for the children are arranged at 6, 12 and
24 months of age at which blood samples are taken. Bone
strength is measured with peripheral quantitative com-
puter tomography (pQCT) at 12 and 24-month follow-up
visits (overview of study follow-up and parameters in
Table 1). During the visit the families meet a study nurse
and have the possibility to meet with a paediatrician.
A total of 875 participants have been to their 12-month
follow-up visit (a drop-out of 112 children) and the 24-
month follow-up visits are ongoing (to date, parents of 36
children have declined to participate in the 24-month
follow-up visit, Fig. 2).
Ethical considerations
An informed consent was obtained from the parents at re-
cruitment. Previous intervention studies have evaluated
Fig. 1 Study protocol. Methods are listed in Table 1 and further described in Additional documentation
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the safety of substitution doses of up to 50 μg vitamin
D in infants [61]. Safety was ensured by performing a
pilot study for the proposed project: 113 children were
randomised into three groups receiving vitamin D3
doses of 10, 30 and 40 μg daily for 3 months [62]. No
hypercalcemia was observed in this study. Plasma and
urine calcium concentrations did not differ between the
three groups and in all groups the mean concentration
of S-25-OHD reached at least 80 nmol/L, which was
considered sufficient. Therefore, 10 μg a day was consid-
ered adequate and ethically sound to use as the dosage for
the control group. While the group receiving 40 μg/day
did not develop hypercalcaemia, their S-25-OHD reached
levels higher than targeted. Dose of 30 μg/day was there-
fore chosen for the present study.
An external steering group was recruited to monitor
the study and possible adverse effects.
The vitamin D3 supplements are prepared by Orion
Pharmaceuticals (Espoo, Finland). The study is researcher
initiated and independent.
The Research Ethics Committee of the Hospital
District of Helsinki and Uusimaa has approved the study
(ID 107/13/03/03/2012) and it is registered into
ClinicalTrials.com (NCT01723852).
Study measures
An overview of study parameters is shown in Table 1. A
full description of specific methods used in the study are
presented in the online Additional documentation. In
brief, the parameters used for the assessment of primary
outcomes are as follows: bone parameters assessed with
pQCT at 12 and 24 months of age, daily infection diary
filled in by parents from 2 weeks to 24 months of age, and
S-25-OHD at birth (cord blood) and at 12 and 24 months
of age.
Data analyses
Differences between groups are tested with relevant statis-
tical models, e.g., independent samples t-test, ANOVA
and analysis of covariance (ANCOVA). Temporal change
and difference between intervention groups of continuous
variables (i.e., S-25-OHD) are assessed with repeated mea-
sures ANCOVA. Furthermore, multivariate and multilevel
regression models adjusted with potential confounders are
applied to explore associations between several outcomes
when applicable.
Table 1 Methods and timing of sampling. Methods are







Vitamin D x x x
Calcium and bone
metabolism
x x x x
Inflammatory markers x x x
DNA x x x
Bone densitometry x x
Infection records x x x




Iron status x x
Dietary survey xa x x x







Mental health and behaviour x x x
Clinical assessment x x x
Health records x x x x
Viral and bacterial swab x x
aretrospectively on maternal diet
Fig. 2 Study recruitment, adherence, and current phase of the study
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Sample size
On the basis of sample size calculation for both of the
primary outcomes, 400 + 400 study subjects, allowing for
a 20% drop-out rate, a 0.2 SD difference can be detected
with p at 0.05 and ß of 0.9. In bone mineral content, a
0.2 SD increase requires 210 + 210 subjects, and a simi-
lar increase in bone cross sectional area 297 + 297 sub-
jects as measured by the same technique as here
(pQCT) [63]. The annual rate of infections in children
below 2 years of age is 6 (SD ± 1.6) [64, 65]. In the group
receiving 30 μg of vitamin D we expect a decrease from
12 to 9 infections during the 24-month study period. A
sample size of 220 + 220 is required to achieve statistical
power.
Discussion
To the best of our knowledge, this is the largest and
most comprehensive randomised intervention study to
assess the effects of vitamin D supplementation on
skeletal and extra skeletal outcomes in infants. To date,
epidemiological studies and randomised intervention
trials have demonstrated conflicting results on, for ex-
ample, the effect of vitamin D supplementation on child-
hood infections and on neurocognitive functioning. This
may be due to difficulties in addressing the multiple
confounding factors affecting the association between ex-
posure and outcome. The present study, based on findings
from a pilot study [62], is designated to specific hypothesis
with adequate statistical power and duration. During the
study, we gather data on infant diet at home and day care,
psychological profiles and atopy-related symptoms using
questionnaires. Results from this study will likely generate
novel evidence-based information for improving vitamin
D status among the paediatric population worldwide. By
analysis of the impact of gene polymorphisms on the
concentration and efficacy of the given vitamin D substi-
tution it may create the basis for individualised dosage
guidelines.
Limitations of the study
Compliance of the study subjects is always an issue in
intervention trials. We are collecting used vitamin D
bottles to evaluate the amount of vitamin D left after each
cycle. These data, and parentally kept diaries on the use of
vitamin D are used to evaluate the compliance in vitamin
D intake.
Questionnaires may be improperly filled, resulting in
missing data on, for example, parent-reported infections.
Therefore, national registers can be used for the valid-
ation of caregiver data.
The results from a study performed in Finland cannot
be directly generalised to other parts of the world. How-
ever, due to the randomised controlled study design our
study will provide valuable data on the effects of vitamin
D substitution in populations with variable vitamin D
status. In addition, the study is designed to have control
over the most common sources of vitamin D.
If the results from the VIDI-trial confirm the connec-
tions between the increased dose of vitamin D and the
primary outcomes, the health benefits gained by a
population-wide supplementation with higher vitamin D
dose— a simple and low-cost intervention— are obvious.
The first results of the VIDI-trial are expected in 2017.
Additional file
Additional file 1: Supplementary documentation. Methods described in
further detail. (DOCX 520 kb)
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